Franklin Resources Inc. Lowers Stake in IQVIA Holdings Inc. $IQV

Franklin Resources Inc. reduced its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 19.4% in the second quarter, according to its most recent filing with the SEC. The fund owned 436,709 shares of the medical research company’s stock after selling 104,892 shares during the period. Franklin Resources Inc.’s holdings in IQVIA were worth $68,821,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Canada Pension Plan Investment Board lifted its stake in IQVIA by 7.3% during the first quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company’s stock worth $810,069,000 after purchasing an additional 312,807 shares during the last quarter. Artisan Partners Limited Partnership purchased a new position in shares of IQVIA during the 2nd quarter valued at about $515,772,000. JPMorgan Chase & Co. lifted its position in IQVIA by 22.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 3,126,171 shares of the medical research company’s stock worth $492,659,000 after buying an additional 581,157 shares during the last quarter. Nordea Investment Management AB boosted its stake in IQVIA by 41.7% in the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock worth $326,274,000 after buying an additional 606,391 shares in the last quarter. Finally, American Century Companies Inc. grew its position in IQVIA by 26.8% during the first quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company’s stock valued at $253,695,000 after acquiring an additional 304,258 shares during the last quarter. Institutional investors own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $228.18 on Tuesday. The company has a current ratio of 0.70, a quick ratio of 0.70 and a debt-to-equity ratio of 2.03. The company has a 50-day moving average price of $206.64 and a 200-day moving average price of $181.78. The company has a market cap of $38.86 billion, a price-to-earnings ratio of 31.30, a price-to-earnings-growth ratio of 2.52 and a beta of 1.34. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $228.77.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The company had revenue of $4.10 billion for the quarter, compared to the consensus estimate of $4.07 billion. During the same quarter in the previous year, the business earned $2.84 EPS. IQVIA’s revenue was up 5.2% compared to the same quarter last year. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, equities analysts anticipate that IQVIA Holdings Inc. will post 10.84 EPS for the current year.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. Cowen lowered shares of IQVIA from a “buy” rating to a “hold” rating in a report on Monday, November 3rd. Hsbc Global Res upgraded shares of IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Thursday, October 9th. UBS Group raised their price objective on IQVIA from $225.00 to $250.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. JPMorgan Chase & Co. boosted their target price on IQVIA from $177.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Finally, TD Cowen lowered IQVIA from a “buy” rating to a “hold” rating and raised their price target for the stock from $206.00 to $215.00 in a research report on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and a consensus price target of $240.61.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 4,000 shares of the firm’s stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total value of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares of the company’s stock, valued at $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.